Sanofi and Regeneron to appeal against Praluent injunction
09-01-2017
360b / Shutterstock.com
A US district court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Regeneron, Sanofi, Amgen, patent, injunction, Praluent, Repatha, Federal Circuit
